Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial
-
Published:2024-03
Issue:
Volume:
Page:
-
ISSN:2588-9311
-
Container-title:European Urology Oncology
-
language:en
-
Short-container-title:European Urology Oncology
Author:
Achard VéraneORCID,
Fournier Béatrice,
D'Haese David,
Krzystyniak Joanna,
Tombal Bertrand,
Roupret Morgan,
Sargos Paul,
Dirix Piet
Reference13 articles.
1. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ);Babjuk;Eur Urol,2022
2. US Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. Silver Spring, MD: FDA; 2018.
3. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021
4. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial;Boorjian;Lancet Oncol,2021
5. LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy;Necchi;Ann Oncol,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献